By
Quratis Inc.
Published: Sept. 6, 2017, 11:03 a.m.·
Tags:
Vaccines
SEATTLE & SEOUL | Aug. 30, 2017: Quratis Inc. announced Wednesday that the company had applied for the phase 2 of clinical trials in Korea for an adult tuberculosis vaccine developed by scientists at the Infectious Disease Research Institute (IDRI). The clinical trial will evaluate the safety and efficacy of the vaccine in the Korean population.
Read More →